Kyverna Therapeutics, Inc. (KYTX)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Kyverna Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 4.91 | 4.93 | 4.81 | 4.84 | 45,495 |
| Nov 6, 2026 | 4.68 | 5.00 | 4.65 | 4.88 | 885,570 |
| Nov 5, 2026 | 5.11 | 5.11 | 4.50 | 4.61 | 1,432,499 |
| Nov 4, 2026 | 5.30 | 5.46 | 5.02 | 5.16 | 974,150 |
| Nov 3, 2026 | 5.28 | 5.48 | 5.12 | 5.16 | 704,672 |
| Nov 2, 2026 | 5.70 | 5.84 | 5.09 | 5.22 | 822,310 |
| Oct 30, 2026 | 5.74 | 5.87 | 5.55 | 5.67 | 640,171 |
| Oct 29, 2026 | 5.91 | 6.12 | 5.83 | 5.85 | 854,640 |
| Oct 28, 2026 | 5.58 | 5.93 | 5.56 | 5.89 | 995,409 |
| Oct 27, 2026 | 5.24 | 5.67 | 5.16 | 5.63 | 916,659 |
| Oct 26, 2026 | 5.35 | 5.41 | 5.18 | 5.27 | 810,112 |
| Oct 23, 2026 | 5.68 | 5.68 | 5.36 | 5.39 | 827,751 |
| Oct 22, 2026 | 5.83 | 5.99 | 5.67 | 5.73 | 519,387 |
| Oct 21, 2026 | 6.15 | 6.30 | 5.80 | 5.84 | 829,516 |
| Oct 20, 2026 | 5.83 | 6.20 | 5.80 | 6.04 | 766,309 |
| Oct 19, 2026 | 5.71 | 5.94 | 5.67 | 5.83 | 837,714 |
| Oct 16, 2026 | 5.94 | 6.05 | 5.64 | 5.67 | 726,279 |
| Oct 15, 2026 | 5.67 | 6.02 | 5.67 | 5.97 | 779,435 |
| Oct 14, 2026 | 5.76 | 5.84 | 5.61 | 5.68 | 1,275,835 |
| Oct 13, 2026 | 6.17 | 6.17 | 5.75 | 5.77 | 1,241,477 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 CLARK IAN T | Director | Grant/Award | 5.1K | -- | May 27, 2026 |
 Cohen Fred E | Director | Grant/Award | 5.1K | -- | May 27, 2026 |
 SEIDENBERG BETH C | Director | Grant/Award | 5.1K | -- | May 27, 2026 |
 Shaw Christi | Executive Chairperson | Automatic Sell | 4.2K | $36.0K | May 27, 2026 |
| SEIDENBERG BETH C | Director | Grant/Award | 20.6K | -- | May 27, 2026 |
| Cohen Fred E | Director | Grant/Award | 20.6K | -- | May 27, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Gilead Sciences, Inc. 2 · also on 13F· may incl. warrants· filed Feb 2024 | 412.6M | 9.0% as filed | 13G |
Vida Ventures, LLC · may incl. warrants· stale · filed May 2024 | 4.8M | 7.7% | 13D |
GordonMD Global Investments LP | 4.2M | 6.9% | 13F |
GILEAD SCIENCES, INC. | 4.1M | 6.7% | 13F |
Westlake BioPartners Fund I, L.P. ("Westlake Fund I") · may incl. warrants· filed Feb 2026 | 3.8M | 6.1% | 13G |
AIGH Capital Management LLC · also on 13F· joint filing· may incl. warrants· filed Oct 2026 | 3.6M | 5.9% | 13G |
AIGH Capital Management LLC | 3.6M | 5.9% | 13F |
BlackRock, Inc. | 3.1M | 5.1% | 13F |
Bain Capital Life Sciences Opportunities III, LP · also on 13F· may incl. warrants· filed Feb 2026 | 3.1M | 5.0% | 13G |
GordonMD Global Investments LP · also on 13F· may incl. warrants· filed Nov 2025 | 3.1M | 4.9% | 13G |
Insiders
- CLARK IAN TDirector
- Cohen Fred EDirector
- SEIDENBERG BETH CDirector
- Shaw ChristiExecutive Chairperson
- Aktar MertDirector
- Martini Gregory S.Chief Financial Officer
- Dac NadiaChief Commercial Officer
- GEHCHAN NAJISee Remarks
- GRASSO MARCChief Financial Officer
- Biddle Warner WestonChief Executive Officer
Top institutional holders
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
based on 61.84M shares outstanding
US30d Avg
822.69K
60d Avg
906.68K
90d Avg
855.25K